The United Kingdom and the United States have announced a key bilateral deal that will keep zero tariffs on British pharmaceutical shipments going into the US market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to raise spending on medicines through the National Health Service (NHS). This pledge secures that duties on these key goods will stay at zero for a timeframe of three years.
This deal is in response to earlier statements to significantly raise import taxes on patented pharmaceutical imports, with potential rates floated as high as one hundred percent.
"This arrangement with the United Kingdom strengthens the worldwide climate for new treatments and introduces much-needed fairness to U.S.–U.K. medicine commerce," a release declared.
Trade Importance
Pharmaceuticals are one of the the United Kingdom's biggest export categories to the US, which is easily the primary buyer for large companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months leading up to last September, the UK shipped drugs totaling over eleven billion pounds to the US. This value accounted for a significant portion of British export trade in that span.
"This agreement safeguards employment, increases funding and facilitates the UK to emerge as a global hub for life sciences," a minister commented.
Specific British Pledges
The deal includes several notable pledges from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to increase total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The percentage manufacturers must return to the NHS to control costs will be restricted at 15%. Previously, repayments were more than 20%.
Industry Background
The deal takes place against a protracted tension between the sector and the ministers over drug pricing and regulatory access.
The disagreement were heightened by claims that American patients were paying several times more for the same drugs than patients in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS must spend more on drugs, noting that its spending on drugs had decreased as a percentage of its total funding over the previous ten-year period.
